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1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: Infantile hypertrophic pyloric stenosis (IHPS) is a common disease in infancy. Pylor-
omyotomy is universally considered the treatment for IHPS; however, oral or intravenous atropine
hasbeen reappraised for the treatment of IHPS in thepast 20 years.We investigated theefficacyof
atropine in the medical management of IHPS by using meta-analysis and investigated the sono-
graphic changes of the pyloric canal, as well as the efficacy and adverse effects of atropine.
Methods: Information was retrieved from PubMed, Ovid, and MEDLINE. The efficacy and adverse
effects of atropine treatment for IHPSwere reviewed using the standard process ofmeta-analysis.
Results: Eleven articles were obtained. Five reports showed that 77 of 110 (70%) infantswhowere
administered oral atropine benefitted by the induced remission of IHPS. Six reports showed that
288 of 345 (83.5%) patients who were treated initially with intravenous atropine then changed
to oral atropine showed beneficial effects and had no serious side effects. Time to pyloric muscle
normalization ranged from 5 weeks to 15 months.
Conclusion: The study results indicate that atropine is a possible alternative treatment for IHPS,
particularly in infants with major concurrent disease, and is safe without obvious side effects.
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516 S.-F. Wu et al1. Introduction
Infantile hypertrophic pyloric stenosis (IHPS) showed a
frequency of 3.9/10,000 live births between 1996 and 2004
in Taiwan.1 The incidence declined to 3/10,000 live births
in 2007 in Taiwan.2 It is the most common cause of vomiting
that requires surgical intervention in infants.3 IHPS is an
abnormal hypertrophy of the muscle of the pylorus. Pylo-
romyotomy, introduced by Dufur and Fredet4 and Fredet5 in
1908 and Ramstedt6 in 1912, has become the first choice of
treatment, as effective surgical intervention can easily be
performed with minimal complications and rare mortality.
In 1955, Corner7 reported on medical treatment using
methyl scopolamine nitrate. A group of workers from
Osaka, Japan, reported a new regimen using intravenous
(IV) methyl atropine nitrate since 19968; thereafter, many
studies have discussed the positive effects of atropine for
treating IHPS. However, the sample size has been relatively
small. Thus, we reviewed all published studies in a meta-
analysis to assess the course and outcome of IHPS
managed with atropine.
2. Materials and methods
2.1. Data sources
This search covered the period from January 1980 through
March 2015. Data were independently extracted by the first
two investigators and then cross-checked by all of the in-
vestigators to avoid any errors. The effects of medical
treatment for IHPS were identified from PubMed, MEDLINE,
and Ovid Medline using the following subject headings
(MeSH) and text word terms: “(Infantile) hypertrophic py-
loric stenosis, medical treatment, atropine therapy.”
The diagnostic criteria for IHPS were repeated projectile
vomiting, and pyloric muscle thickening 3e4 mm and
pyloric canal length 14e18 mm on ultrasonography.
The selection criteria were as follows: (1) pediatric
studies; (2) definite diagnosis of hypertrophic pyloric ste-
nosis in infants using definite diagnostic standards; and (3)
experiments analyzing the curative effect of atropine for
pyloric stenosis. Case reports were excluded. The quality of
each paper was evaluated using the modified Jadad scale9
based on the adequacy of randomization, blinding, and
follow up, with a maximum score of 8 points.
For each study, the date of publication, sample size, pa-
tient characteristics, treatment method, side effects, and
outcomes were recorded. Successful treatment was defined
as patients free from vomiting and steady weight gain.
2.2. Statistical analysis
Data for the successful proportion of medical treatment for
IHPS in several studies covering the study period were
pooled. The degree of heterogeneity among these studies
was shown using the Q statistic and I2 statistic. If the p value
of the Q statistic was smaller than the significant level or if
I2 was >40%, then there was heterogeneity among the
studies and the proportions were pooled using the random
effect model. If there was homogeneity among studies, thefixed effect model was used to pool proportions. Signifi-
cance was set at 0.05. Sensitivity analysis was conducted to
explore the effect of excluding outliers on the pooled esti-
mate. The funnel plot of the logit event rate against the
standard error was assessed for publication bias. In addition,
we reanalyzed the data by excluding studies with poor
quality (modified Jadad score, 3). Formal statistical
testing included an adjusted rank correlation test and a
regression asymmetry test.10,11 Meta-analysis was per-
formed using the software Comprehensive Meta-Analysis
(version 2.2.064; Biostat, Englewood, NJ, USA; 2005).3. Results
Twelve articles8,12e22 were obtained in the search
(Figure 1). Table 1 summarizes the key characteristics of
the 12 articles. Among them, the report of Kawahara et al19
in 2005 included the same study participants recruited in
the report of Kawahara et al15 in 2002. As such, we
excluded the study of Kawahara et al15 published in 2002.
Overall, a total of 11 studies were enrolled in this meta-
analysis study. Three studies used oral atropine alone,
whereas six studies used IV atropine initially, then
substituted oral atropine. In two studies, atropine was
given orally, then intravenously if ineffective. Oral atropine
was given at an initial dose of 0.05 mg/kg/d and increased
to a maximum dose of 0.1 mg/kg/d. The dose of IV atropine
was started at 0.04e0.06 mg/kg/d and increased by
0.01 mg/kg/d until vomiting ceased. The IV atropine was
then changed to oral atropine at twice the effective IV
dose.
Treatment was discontinued under the following condi-
tions: ultrasonography showed normalization of pyloric
muscle thickness; passage of food through a wide channel
on ultrasonography; the patient started gaining weight;
vomiting ceased and then resumed for 2e3 weeks; or
vomiting ceased and oral atropine was continuously used
until the age of 10 weeks.
Five reports showed that in 110 patients receiving oral
atropine, 77 (70%) patients showed beneficial effects in
that treatment induced remission of IHPS whereas three
cases converted to IV atropine. Six reports with a total of
345 patients who received IV atropine followed by oral
atropine showed IHPS remission in 288 (83.5%) patients. The
mean duration of medical therapy was 24e63 days.
The patients treated successfully with atropine showed
steady weight gain. Three studies showed a mean weight
gain of 17e30 g/d during the admission period in the
groups with successful atropine therapy.15,16,21 The body
weight range on admission was from below the 3rd to the
25th percentile, and after 1 month of IV atropine treat-
ment, the body weight range was from the 10th to 75th
percentile in the study of Huang and Su.16 Kawahara et al15
reported a significant increase in body weight during
atropine treatment by comparing body weight at 6 months
of age with that at presentation. The adverse effects
related to the use of IV atropine included flushing (7/184,
3.8%), tachycardia (14/184, 7.6%), and transient increase
in serum alanine aminotransferase (ALT) level (12/184,
6.5%). There was no adverse effect related to the use of
oral atropine.
16 arƟcles were enrolled
4 arƟcles were excluded.
.
.
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1 case report
1 leƩer
12 arƟcles
11 arƟcles
1 arƟcle was excluded because the same study
parƟcipants were recruited in one of the 12 arƟcles
2 arƟcles that did not discuss the treatment methods
Figure 1 Study selection process. The flowchart summarizes the selection of studies including numbers and reasons why some
studies were excluded.
Atropine treatment for IHPS 517In the present study, I2 was 70.2% and the p value of the
Q statistic was <0.001, which indicated significant vari-
ability among studies. The random effect model was
selected to pool the proportions to estimate the overall
proportion and the forest plot of the 11 included trials
(Figure 2). The overall proportion of effective treatment
with atropine was 0.806 [95% confidence interval (CI),
0.708e0.876; p < 0.01]. Ten trials had similar proportionsTable 1 Demographic data of the 12 studies.
Author Atropine group
(successful
cases/total cases)
Age at admission
weeks)
Birth
weight
Nagita A.8 21/23 7.8 (mean) NA
Yamataka A.12 11/14 11.4 (mean) 3046
(mean)
Riccabona M.13 7/22 6 (mean) NA
Singh UK.14 50/52 NA NA
Kawahara H.15,* 17/19 6.6 (median) 3192
(media
Huang YC.16 5/5 4.4 (mean) 2911
(mean)
Sretenovic A.17 18/22 3-12 NA
Singh UK.18 11/12 4.1 NA
Kawahara H.19 45/52 5.7 (median) 2981
(media
Meissner PE.20 25/33 5.0 (mean) NA
Lukac M.21 30/40 3.2 (mean) NA
Takeuchi M.22 142/180 5.7 (mean) NA
Abbreviation: NA, not available.
* The report by Kawahara H19 included the same study subjects rec
was excluded in this study.to the overall proportion and a strong tendency for suc-
cessful treatment. Only one trial showed ineffective
treatment (proportion, 0.318). The study by Huang and Su16
had the largest variance and lowest pooling weight in the
meta-analysis procedure (95% CI, 0.378e0.995).
A sensitivity analysis was performed to explore the ef-
fect of outliers on the pooled estimate by removing the
study of Kawahara et al,15 who reported a success rate two(g)
Weight at
admission (g)
Days to
arrest
vomiting
Hospital
stay (days)
Publish
date
3658 (mean) 5.1 (mean) NA 1996
3622 (mean) NA NA 2000
NA NA NA 2001
NA NA NA 2001
n)
4043 (median) NA 13 2002
4000 (mean) 1.8 (mean) 14.6 2004
NA 3.3 (mean) NA 2004
NA 17.1 (mean) 2 2005
n)
3730 (median) NA 13 (median) 2005
3860 (mean) 5.8 (mean) NA 2006
3680 (mean) 7 (mean) 8 (mean) 2013
NA NA 13.5 (median) 2013
ruited in the report by Kawahara H15. The study of Kawahara H15
Figure 2 Forest plot of 11 enrolled studies.
518 S.-F. Wu et altimes lower than that of the other 10 studies (0.318 vs.
0.750e0.962). After the study was removed, the I2 value
decreased from 70.2% to 23.99%. The summary event rate
changed from 0.806 (95% CI, 0.708e0.876) to 0.811 (95% CI,
0.769e0.846). This result was not sensitive to the outlier. In
addition, we reanalyzed the data by excluding the low-
quality studies, and the result [summary event rate, 0.791
(95% CI, 0.742e0.832); p < 0.001; five trials, n Z 319;
heterogeneity, p Z 0.679) was consistent with that ob-
tained by pooling all available studies.
The funnel plot (Figure 3) displaying logit event rates of
the individual studies versus the reciprocal of their stan-
dard errors showed no substantial asymmetry for studies
that explored the effect of atropine on IHPS (p Z 0.28 by
the adjusted rank correlation test; p Z 0.45 by Egger
regression asymmetry test). Table 2 shows the evidence-
based medicine (EBM) level and quality of the papers
evaluated using the modified Jadad scale. The EBM levelFigure 3 Funnel plot of standawas based on the study design and the quality of each
study. All papers were ranked as Level 4 evidence. For the
quality of papers evaluated using the modified Jadad scale,
five (45.5%) of 11 papers achieved a score of 4, three
(27.3%) were awarded a score of 3, and three (27.3%) were
given a score of 2.
4. Discussion
This meta-analysis shows that either oral or IV atropine
sulfate was an effective treatment for IHPS in all but one
study.
The etiology of IHPS remains unclear although several
hypotheses have been postulated, including impaired
function of acetylcholine and muscarinic receptors,
decreased nitric oxide synthase activity, elevated prosta-
glandin and gastrin levels, infectious causes, and a genetic
basis.23e28 The mechanism of atropine sulfate in IHPSrd error by logit event rate.
Table 2 EBM level and quality of papers evaluated by
modified Jadad scale.
Study EBM level Blinding Modified
Jadad scale
Score
Nagita A.8 4 No 3
Yamataka A.12 4 No 4
Riccabona M.13 4 No 3
Singh UK.14 4 No 3
Huang YC.16 4 No 2
Sretenovic A.17 4 No 2
Singh UK.18 4 No 2
Kawahara H.19 4 No 4
Meissner PE.20 4 No 4
Lukac M.21 4 No 4
Takeuchi M.22 4 No 4
The score for each article can range from 0 (lowest quality) to 8
(highest quality). Scores of 4e8 represent good to excellent
(high quality) and 0 to 3 poor or low quality.
Atropine treatment for IHPS 519therapy mainly involves a cholinergic blocking agent with
potent antimuscarinic activity that decreases peristaltic
contractions by relaxing the pyloric smooth muscles.29 The
effective range varies widely, perhaps because of the al-
terations in the muscarinic receptor sensitivity of the
muscle,29 variations in drug clearance, compromised blood
flow secondary to pyloric spasm, lack of nitric oxide syn-
thase, and poor innervation of the pyloric circular
musculature.23,24,30
The pharmacologic activity of IV atropine is 2e3 times
greater than that of the oral form, with faster response to
the effective IV dose. However, the IV form may be asso-
ciated with more adverse effects, the most common of
which are transient tachycardia and flushing. Oral atropine
is absorbed from the intestines. Dilution with gastric con-
tents and delayed emptying may prevent the desired
amount reaching the intestines in the desired time. In this
study, 70% of patients receiving oral atropine and 83.5% of
patients receiving IV atropine initially followed by oral
atropine benefitted from induced remission of IHPS. Initial
IV atropine is more effective than oral atropine for treating
IHPS despite the transient increase in serum ALT of
3.8e7.6%, which resolves without intervention. Mercer and
Phillips31 reported a success rate of 88% for conservative
therapy with atropine in patients with IHPS. The result was
gained from 10 studies pooled in a meta-analysis.8,12e20
This study differed from our study in that the study of
Kawahara et al15 was not excluded and there was no sta-
tistical distinction between treatment with oral atropine
only and initial IV atropine in the results.
Most studies show that vomiting ceases within 7 days,
with earlier improvement than the time of normalization of
the pyloric canal in medically treated groups. Singh et al14
reported that vomiting ceased in 1e3 days, 4e7 days, and
9e12 days in patients with mild, moderate, and severe
pyloric hypertrophy, respectively. However, the success
rate was not different among the three groups, all of which
received medical treatment. Kawahara et al19 demon-
strated a statistical difference in body weight (3885 g vs.3230 g) at the time of presentation when comparing pa-
tients with successful and unsuccessful atropine therapy.
However, Meissner et al20 reported no difference in body
weight at admission between these two groups. Pyloric
canal normalization after treatment is evaluated by ultra-
sonography. Nagita et al8 reported that time to normali-
zation of pyloric muscle thickness ranged from 4 months to
12 months. Yamataka et al12 reported that time to
normalization of pyloric muscle thickness averaged
3.4  2.3 months, with no significant difference in the
pyloromyotomy group (3.8  2.0 months), whereas Singh
et al14 reported 3e15 months after completion of oral
therapy. Kawahara et al15 reported that pyloric muscle
thickness decreased significantly from 5 mm at presenta-
tion to 3 mm 3 weeks after completion of oral atropine
treatment. In a report in 2004,16 three of five patients
receiving oral atropine had normalization of the pyloric
canal in 35e47 days. In all of these reports, time to pyloric
muscle normalization ranged from 5 weeks to 15 months for
groups treated with atropine.
There were no adverse effects or complications related
to the use of oral atropine in four studies. Thus, oral
atropine is a simpler and safer treatment than IV atropine
for treating IHPS. There are three reports15,16,19 that used
IV atropine for IHPS with a hospital stay of 13e14 days
(13 days, 14.6  6.2 days, and 13 days). Only one study18
treated IHPS with oral atropine with a hospital stay of
1e2 days. Begg and Mazumdar9 compared atropine and
pyloromyotomy for managing IHPS and showed no differ-
ence in length of hospitalization, whereas three
reports20e22 cited prolonged hospital stay in the medical
groups (12 days vs. 7 days in 2006, 8 days vs. 4 days, and
13 days vs. 8 days in 2013 for medical and surgical treat-
ment, respectively).
In terms of costs, expenses were lower in the atropine
group than in the pyloromyotomy group in one report.12
However, in the studies of Kawahara et al19 and Takeuchi
et al,22 the cost in medically treated cases was not signif-
icantly different than that in cases treated by pylo-
romyotomy alone because of the prolonged hospitalization
in the medical cases.
This meta-analysis shows a strong tendency for suc-
cessful treatment except in the report of Riccabona et al13
(Figure 2), which had a 32% success rate for medical
treatment. In this study, there was a difference in mean
pyloric length of 15 mm in patients with successful medical
treatment versus 18 mm in patients who underwent sur-
gery. These findings can perhaps explain the low success
rate in patients who received conservative treatment.
However, the success rate increased to 77% in younger
patients (age, <6 weeks). Thus, it is worthwhile to conduct
atropine therapy in infants with IHPS prior to going directly
to surgery. The standard process of meta-analysis is that
articles should be extracted from randomized control trials.
There were only three studies12,21,22 that randomized pa-
tients into medical or surgical treatment for IHPS, and the
cure rate of patients in surgical groups was 97e100%.
Pyloromyotomy is no doubt a very effective treatment for
IHPS and has a shorter length of stay in hospital than
medical treatment. Surgical treatment is recommended in
patients with severe dehydration and hematemesis, where
medical treatment is inadequate. However, it is associated
520 S.-F. Wu et alwith the risk of perforation of the stomach or duodenum,
wound infection, wound dehiscence, and the risk of anes-
thesia, although these complications are infrequent. Future
studies should focus on the randomization, growth rate,
and neurodevelopment outcome between medically and
surgically treated groups.
Although the current meta-analysis provided useful in-
formation, a potential limitation of this study is the quality
of included studies, which varied from low to high. Only five
of 11 papers12,19e22 were of high quality (Jadad score, 4),
whereas the other papers were of low quality. More high-
quality studies are needed in the future. However, by
performing sensitivity analyses that only included high-
quality studies, the result was consistent with that ob-
tained by pooling all available studies. It is unlikely that this
shortcoming affected the findings.
In conclusion, medical treatment with either oral or IV
atropine is a good alternative to pyloromyotomy for IHPS
patients, particularly in infants with major concurrent
disease or when parents are unwilling to let their infants
undergo surgery. Oral atropine has less adverse effects than
IV atropine for treating IHPS. Parents should be informed of
this before they make their own decision.Conflicts of interest
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